Fig. 2

Accumulation of [¹¹¹In]In-FnBPA5 and the control peptide [¹¹¹In]In-FnBPA5 scr in the uterus and the ovaries according to the estrous cycle stage of the mouse 24 h after i.v. injection. While the uterus accumulation of [¹¹¹In]In-FnBPA5 is mediated by the estrous cycle, with increased uptake during proestrus and estrus, uptake of [¹¹¹In]In-FnBPA5 in the ovaries is unaffected by hormonal changes. In contrast to [¹¹¹In]In-FnBPA5, the scrambled control [¹¹¹In]In-FnBPA5 scr displays only background uptake in both uterus and ovaries independent of the estrous cycle stage of the mouse. Statistical significance was assessed using Kruskal–Wallis and Dunn’s post hoc test with *p < 0.05. n = 6 (proestrus), 4 (estrus), 7 (metestrus), 12 (diestrus) for [¹¹¹In]In-FnBPA5 and n = 3 (proestrus), 2 (estrus), 5 (metestrus), 10 (diestrus) for [¹¹¹In]In-FnBPA5 scr